HomeCompareMPLN vs EQR

MPLN vs EQR: Dividend Comparison 2026

MPLN yields 8.64% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $12.4K in total portfolio value· pulled ahead in Year 5
10 years
MPLN
MPLN
● Live price
8.64%
Share price
$23.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.4K
Annual income
$1,490.69
Full MPLN calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — MPLN vs EQR

📍 EQR pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMPLNEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MPLN + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MPLN pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MPLN
Annual income on $10K today (after 15% tax)
$734.34/yr
After 10yr DRIP, annual income (after tax)
$1,267.09/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $3,387.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MPLN + EQR for your $10,000?

MPLN: 50%EQR: 50%
100% EQR50/50100% MPLN
Portfolio after 10yr
$41.6K
Annual income
$3,483.14/yr
Blended yield
8.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

MPLN
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Price Target
$10.00
-56.8% upside vs current
Range: $10.00 — $10.00
Altman Z
-0.4
Piotroski
5/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MPLN buys
0
EQR buys
0
No recent congressional trades found for MPLN or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMPLNEQR
Forward yield8.64%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$35.4K$47.8K
Annual income after 10y$1,490.69$5,475.61
Total dividends collected$11.8K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$10.00$70.35

Year-by-year: MPLN vs EQR ($10,000, DRIP)

YearMPLN PortfolioMPLN Income/yrEQR PortfolioEQR Income/yrGap
1$11,564$863.93$11,380$679.82+$184.00MPLN
2$13,307$933.69$13,014$837.25+$293.00MPLN
3$15,243$1,004.14$14,961$1,036.20+$282.00MPLN
4$17,385$1,074.96$17,297$1,289.22+$88.00MPLN
5← crossover$19,747$1,145.80$20,121$1,613.15$374.00EQR
6$22,346$1,216.38$23,561$2,030.84$1.2KEQR
7$25,197$1,286.41$27,783$2,573.54$2.6KEQR
8$28,316$1,355.62$33,013$3,284.39$4.7KEQR
9$31,722$1,423.78$39,547$4,223.51$7.8KEQR
10$35,433$1,490.69$47,791$5,475.61$12.4KEQR

MPLN vs EQR: Complete Analysis 2026

MPLNStock

MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.

Full MPLN Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this MPLN vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MPLN vs SCHDMPLN vs JEPIMPLN vs OMPLN vs KOMPLN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.